Compare Divis Laboratories with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs CADILA HEALTHCARE - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES CADILA HEALTHCARE DIVIS LABORATORIES/
CADILA HEALTHCARE
 
P/E (TTM) x 50.2 25.1 199.7% View Chart
P/BV x 13.4 4.4 304.5% View Chart
Dividend Yield % 0.5 0.8 58.1%  

Financials

 DIVIS LABORATORIES   CADILA HEALTHCARE
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
CADILA HEALTHCARE
Mar-20
DIVIS LABORATORIES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,639352 465.3%   
Low Rs1,115207 540.0%   
Sales per share (Unadj.) Rs186.3139.2 133.8%  
Earnings per share (Unadj.) Rs51.011.8 433.1%  
Cash flow per share (Unadj.) Rs57.318.6 308.7%  
Dividends per share (Unadj.) Rs16.003.50 457.1%  
Dividend yield (eoy) %1.21.3 92.7%  
Book value per share (Unadj.) Rs261.8101.4 258.3%  
Shares outstanding (eoy) m265.471,023.74 25.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.42.0 368.3%   
Avg P/E ratio x27.023.7 113.8%  
P/CF ratio (eoy) x24.015.0 159.7%  
Price / Book Value ratio x5.32.8 190.8%  
Dividend payout %31.429.8 105.5%   
Avg Mkt Cap Rs m365,592286,033 127.8%   
No. of employees `00011.813.4 88.4%   
Total wages/salary Rs m5,42324,145 22.5%   
Avg. sales/employee Rs Th4,175.110,632.7 39.3%   
Avg. wages/employee Rs Th457.71,801.2 25.4%   
Avg. net profit/employee Rs Th1,141.8898.5 127.1%   
INCOME DATA
Net Sales Rs m49,463142,531 34.7%  
Other income Rs m1,5561,139 136.6%   
Total revenues Rs m51,019143,670 35.5%   
Gross profit Rs m18,71824,198 77.4%  
Depreciation Rs m1,6896,965 24.2%   
Interest Rs m353,418 1.0%   
Profit before tax Rs m18,55114,954 124.1%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0233,198 157.1%   
Profit after tax Rs m13,52712,044 112.3%  
Gross profit margin %37.817.0 222.9%  
Effective tax rate %27.121.4 126.6%   
Net profit margin %27.38.5 323.7%  
BALANCE SHEET DATA
Current assets Rs m46,50187,154 53.4%   
Current liabilities Rs m8,46882,694 10.2%   
Net working cap to sales %76.93.1 2,457.3%  
Current ratio x5.51.1 521.1%  
Inventory Days Days13171 183.1%  
Debtors Days Days8694 91.5%  
Net fixed assets Rs m25,797133,236 19.4%   
Share capital Rs m5311,024 51.8%   
"Free" reserves Rs m68,962102,733 67.1%   
Net worth Rs m69,493103,757 67.0%   
Long term debt Rs m032,146 0.0%   
Total assets Rs m80,383236,866 33.9%  
Interest coverage x531.05.4 9,879.3%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.6 102.3%   
Return on assets %16.96.5 258.5%  
Return on equity %19.511.6 167.7%  
Return on capital %26.713.7 194.8%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23852,752 78.2%   
Fx outflow Rs m12,40514,504 85.5%   
Net fx Rs m28,83338,248 75.4%   
CASH FLOW
From Operations Rs m9,54325,054 38.1%  
From Investments Rs m-6,854-10,123 67.7%  
From Financial Activity Rs m-2,459-10,942 22.5%  
Net Cashflow Rs m2303,989 5.8%  

Share Holding

Indian Promoters % 52.0 74.8 69.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 8.3 142.2%  
FIIs % 19.0 5.9 322.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 11.0 156.4%  
Shareholders   31,796 44,069 72.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  ASTRAZENECA PHARMA  BIOCON   

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat, GAIL and UPL Among Top Nifty Gainers(Closing)

Indian share markets continued their volatile trend during closing hours today and ended their day on a flat note.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Mar 8, 2021 03:32 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - NOVARTIS COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS